Burrill & Company
VC Fund
San Francisco, United States
Burrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
- Total investments:
- 60
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Burrill & Company invests in
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Stages Burrill & Company invests in
Series BFunding RoundSeries ASeries CSeries D
Countries Burrill & Company invests in
United States
Contacts
Investment Focus
Industry
- Biotechnology 31 (52%)
- Health Care 24 (40%)
- Medical 14 (23%)
- Pharmaceutical 11 (18%)
- Therapeutics 6 (10%)
Stage
- Series B 14 (23%)
- Funding Round 11 (18%)
- Series A 10 (17%)
- Series C 7 (12%)
- Series D 5 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Irena Melnikova
Managing Director
|
Managing Director | Total investments: 7 | Find email | |
Anna G. Annenko
Business Development Manager
|
Business Development Manager | Total investments: 0 | Find email | |
Ann F. Hanham
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Eduardo Marques de Souza Dantas Matto
Associate
|
Associate | Total investments: 0 | Find email | |
Holly Apgar
Director
|
Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neos Therapeutics
|
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $20.6M / Feb 19, 2015 | |
Nora Therapeutics
|
Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine.Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF)procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. | $18M / Series B / Apr 17, 2014 | |
|
Neos Therapeutics
|
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $15.5M / Series C / Mar 04, 2014 | |
Gyre Therapeutics
|
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. | Post-IPO Equity / Apr 01, 2013 | |
Odyssey Thera
|
Odyssey Thera, Inc., a biopharmaceutical company, develops cellular pharmacology strategy for the identification of medicines for human diseases. It focuses on the identification and development of treatment therapies for cancer. The company was formerly known as Odyssey Pharmaceuticals. Odyssey Thera, Inc. is based in San Ramon, California. | $2.8M / Feb 14, 2013 | |
Cobalt Technologies
|
Cobalt Technologies develops technologies that focuses and designed for biofuels. Cobalt is pioneering science that makes possible a new generation of fuels that burn cleaner, are more cost-effective and have a smaller environmental impact. It was founded in 2005 and headquartered in Mountain View, California. | $5M / Oct 01, 2012 | |
|
Gyre Therapeutics
|
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. | Post-IPO Equity / Sep 25, 2012 | |
AliveCor
|
AliveCor has a device and application that will turn any smartphone into a clinical-quality electrocardiogram (ECG) recorder. AliveCor is pioneering the creation of FDA-cleared 'machine learning' techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. It specializes in the fields ofhealthcare, mobile device, and medicine.It was founded in 2010 and headquartered in Mountain View, California. | $10.5M / Series B / Jun 10, 2012 | |
Ceptaris Therapeutics
|
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topicalmechlorethamine product available to treat the signs and symptoms of this rare cancer. | $10M / Series D / Jun 05, 2012 | |
WhiteGlove Health
|
WhiteGlove Health has become a leader in the healthcare industry through providing an extraordinary healthcare experience for members and providing significant cost savings for health plans through reduced insurance claims and reductions in unnecessary utilization. Their comprehensive healthcare strategy is to provide the highest quality care at apredictable cost through highly-skilled nurse practitioners supported by registered nurses in collaboration with physicians, hospitals, other health care providers and carriers.Since 2007, WhiteGlove Health’s highly trained and experienced clinical team comprised of board-certified Nurse Practitioners and Registered Nurses have been making house calls, office calls and providing telephonic support to help members feel better, faster. Their initial focus as a mobile healthcare provider for acute needs and managing chronic conditions has paved the way for the successful introduction of their Value-Based Care division in 2014 which leverages their clinical expertise and ability to deliver provider care to high risk/high cost patients for their Medicare and Medicaid health plan customers. Value-Based Care is conducted at-home or at a Skilled Nursing Facility (SNF) and allows health plans the ability to care for their most challenging patients.Their Solution offers care designed to reduce hospital admissions, re-admissions and prevent unnecessary visits to an emergency room. A WhiteGlove Health Nurse Practitioner has the ability to order or discontinue medications, add home health or durable medical Equipment (as needed) and routinely communicate with the Primary Care Physician on behalf of the patient. The WhiteGlove Health strategy of prompt follow-up and proactive intervention allows us to carefully monitor patients and manage utilization.In June 2014, WhiteGlove Health acquired Glenridge Healthcare Solutions, a leading consulting, technology and professional services firm, founded in 1997 and headquartered in Maryland. Together, their companies are creating more opportunities and efficiencies than they could have achieved independently. Glenridge continues to partner with customers nationwide by providing a seasoned team, advanced data analytic capabilities and state-of-the art technology to their established impressive portfolio. | $12.9M / Series E / Apr 12, 2012 | |
| See all 60 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Burrill & Company invest in?
Burrill & Company invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Burrill & Company?
Public channels for Burrill & Company include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Burrill & Company?
The team at Burrill & Company includes Irena Melnikova (Managing Director), Anna G. Annenko (Business Development Manager) and Ann F. Hanham (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
